Dr Shore On The Approval Of Radium 223

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

More on prostate cancer: onclive.com/specialty/prostate-cancer

  • Dr. Shore on the Approval of Radium-223 ( Download)
  • Dr. Neal D. Shore on the Approval of Radium-223 ( Download)
  • Dr. Shore on Patient Considerations Following Treatment With Radium-223 ( Download)
  • Dr. Shore Discusses Patient Considerations With Radium-223 ( Download)
  • Radium-223: Treatment Considerations ( Download)
  • Dr. George Discusses Radium-223 for Patients With mCRPC Part I ( Download)
  • Bone-migrated prostate cancer and Radium-223 therapy ( Download)
  • Dr. Daniel George on the Incorporation of Radium-223 in Advanced Prostate Cancer ( Download)
  • Dr. Sartor Discusses the Novel Agent Radium-223 ( Download)
  • Dr. Shore Reviews Emerging Therapies in Prostate Cancer ( Download)
  • Dr. Daniel George on Radium-223 in Combinations for Metastatic Castration-Resistant Prostate Cancer ( Download)
  • Sartor: Expanded Access Program for Radium-223 (Xofigo) ( Download)
  • Radium-223 in Combination Therapy for mCRPC ( Download)
  • Dr. Saad on Radium-223 in Patients with mCRPC ( Download)
  • Dr. Leonard Gomella on Radium-223 in Advanced Prostate Cancer ( Download)

Author

Ariyani

Como educador, estou profundamente engajado no desenvolvimento dos estudantes em ambiente escolar, adotando métodos pedagógicos que valorizam conexões genuínas e são movidos por inovação e fervor. É minha vocação guiar os alunos na jornada de se tornarem uma geração notável, empregando estratégias de ensino amplamente aclamadas por prestigiadas instituições acadêmicas ao redor do globo - events.zulekhahospitals.com